Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBITUZUMAB
Document Type and Number:
WIPO Patent Application WO/2019/017499
Kind Code:
A3
Abstract:
The present disclosure relates to administration speed of obinutuzumab.

Inventors:
WENGER MICHAEL (CH)
MOBASHER MEHRDAD (US)
LIN CHIN-YU (US)
Application Number:
PCT/JP2018/038924
Publication Date:
February 21, 2019
Filing Date:
October 19, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HOFFMANN LA ROCHE (CH)
International Classes:
C07K16/28; A61K39/395; A61P35/00
Domestic Patent References:
WO2016024228A12016-02-18
Foreign References:
Other References:
TOBINAI KENSEI ET AL: "A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies", ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 34, no. 2, 21 December 2016 (2016-12-21), pages 324 - 356, XP036181746, ISSN: 0741-238X, [retrieved on 20161221], DOI: 10.1007/S12325-016-0451-1
TSUJIMURA HIDEKI: "Safety and Tolerability of Obinutuzumab (GA101) with Shorter Duration of Infusion in Japanese Patients with Previously Untreated CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)-Comparison with GAO4915g (GATHER) and BO21005 (GOYA) Studies | Blood Journal", 58TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 03 -06, 2016, vol. 128, 2 December 2016 (2016-12-02), pages 5389, XP055539128
GUILLAUME CARTRON ET AL: "Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study", BLOOD, vol. 124, no. 14, 20 August 2014 (2014-08-20), pages 2196 - 2202, XP055539219, DOI: 10.1182/blood-2014-07-
Attorney, Agent or Firm:
SONODA & KOBAYASHI INTELLECTUAL PROPERTY LAW (JP)
Download PDF: